US Corporate Board Director Changes SEC Filings — April 07, 2026

07-04-2026

On April 1, 2026, Consolidated Water Co. Ltd. promoted Douglas Vizzini from Vice President of Finance to Executive Vice President and Chief Accounting Officer and entered into an employment agreement with him effective that date through December 31, 2027, with potential two-year extensions at the CEO's discretion. The agreement includes an annual base salary of $350,000, a targeted short-term incentive of 25% of base salary, annual RSU grants valued at 20% of base salary, and a monthly automobile allowance starting at $1,750. Termination provisions include severance equal to one year's base salary if not extended, immediate termination for cause, and provisions for incapacity or resignation with six months' notice.

• ·RSUs vest one-third annually over three fiscal years, subject to continued service.
• ·Severance of one year's base salary if CEO elects not to extend term.
• ·Termination for felony conviction or material harm (with 10-day cure period); resignation requires six months' notice.
• ·Incapacity provisions: duties relieved after 60 days, salary reduced to $1,000/year, full medical coverage until recovery; auto-termination after 12 months.

07-04-2026

S&T Bancorp, Inc. and S&T Bank entered into an amended and restated employment agreement with CEO Christopher McComish, effective January 1, 2026, for a four-year term with automatic annual renewals. The agreement sets a minimum annual base salary of $785,000, target annual bonus of 67% of base salary, and long-term incentive awards with target value of at least 100% of base salary (50% time-vesting, 50% time- and performance-vesting). It includes severance of 2x (or 3x within two years post-change in control) base plus target bonus, COBRA premiums for 24 (or 36) months, and other perks like up to $25,000 annual vehicle allowance and $25,000 legal fee reimbursement, plus one-year post-termination non-compete and non-solicit covenants.

• ·Employment agreement has a four-year initial term with automatic one-year renewals.
• ·Severance benefits conditioned on execution of a release of claims.
• ·Perpetual covenants for nondisclosure of confidential information and non-disparagement.
• ·Non-competition and non-solicitation covenants apply for one year post-termination.

07-04-2026

Xponential Fitness, Inc. announced its Board of Directors has initiated a review of strategic alternatives to maximize shareholder value, potentially including a sale, merger, or other transaction, and engaged Jefferies LLC as financial advisor. Separately, the Board appointed Nicole Parent Haughey as an independent director, while Jair Clarke, Chelsea A. Grayson, and Bruce Haase stepped down from the Board. CEO Mike Nuzzo stated the team will continue executing its strategy amid the process.

• ·Operates franchise, master franchise, and international expansion agreements in 49 U.S. states, Puerto Rico, and 28 additional countries.
• ·Nicole Parent Haughey previously served as COO of Island Creek Oysters and Mimeo, and held roles at Vertical Research Partners, United Technologies, and Credit Suisse.
• ·References risks in Annual Report on Form 10-K for year ended December 31, 2025.

07-04-2026

Protagenic Therapeutics, Inc. notified Alexander Arrow, MD, its Chief Financial Officer, that his employment will be terminated effective April 30, 2026, with the board notification occurring on March 31, 2026. No replacement has been announced, representing a key leadership transition. The filing was signed by Executive Chairman Garo H. Armen.

• ·Filing signed on April 6, 2026, and dated April 7, 2026

07-04-2026

Velo3D, Inc. appointed James Suva as Chief Financial Officer and principal financial and accounting officer, effective April 6, 2026, as previously disclosed on March 20, 2026. Under the offer letter effective March 5, 2026, Mr. Suva receives an annual base salary of $380,000 and a target bonus for fiscal 2026 equal to 70% of his base salary. The Compensation Committee granted 135,000 RSUs vesting 25% on May 15, 2027, and 1/16th quarterly thereafter subject to continued service.

• ·Offer letter entered April 6, 2026, effective March 5, 2026; at-will employment with customary confidentiality covenants
• ·RSU vesting on Quarterly Vest Dates: February 15, May 15, August 15, November 15
• ·Offer letter filed as Exhibit 10.1

07-04-2026

Green Stream Holdings Inc. reported changes in control via officer and director transitions: James C. DiPrima resigned as an officer on March 17, 2026, and as a director on March 19, 2026, while Phil Yang was appointed as Vice President, Chief Executive Officer, Secretary, Treasurer, and Director on March 18, 2026, owning no shares. The company redomiciled from Wyoming to California. No financial impacts or performance metrics were disclosed.

• ·Phil Yang's professional background includes overseeing mortgage processing at Direct Mortgage Investors, Inc. (2019-2023), private mortgage loans, and recent commercial asset acquisitions in Rochester, NY, and Washington DC.
• ·Phil Yang holds BA in Government and International Politics, BS in Public Administration (George Mason University, 2016), and MA in International Security (George Washington University, 2018).

07-04-2026

On April 1, 2026, Opus Genetics, Inc. entered into Change in Control Bonus Payment Agreements with four key executives: CEO Dr. George Magrath, CFO Robert Gagnon, COO Joseph Schachle, and Chief Scientific and Development Officer Dr. Ashwath Jayagopal. The agreements provide for reimbursement of any excise taxes incurred by the executives under Section 4999 of the Internal Revenue Code in connection with a change in control of the Company. The full text is filed as Exhibit 10.1.

• ·Trading symbol: IRD
• ·Incorporated in Delaware; Commission File Number: 001-34079; IRS EIN: 11-3516358
• ·Principal executive offices: 8 Davis Drive, Durham, NC 27713
• ·Filing signed by Dr. George Magrath on April 7, 2026

07-04-2026

WW International, Inc. (Nasdaq: WW) appointed Lisa Gavales and Sue Gove as independent directors to its Board, effective April 7, 2026, bringing expertise in consumer brands, digital commerce, retail turnaround, and financial leadership. Following the appointments, the Board consists of six independent directors, who will serve until the 2026 annual meeting of shareholders. The additions support the Company's strategic transformation into a global leader in weight health, including GLP-1 era offerings.

• ·Lisa Gavales: Chair of Office of the CEO at Destination Maternity, Interim CEO of Bluestem Group, former CMO at Express.
• ·Sue Gove: Former President and CEO of Bed Bath & Beyond, CEO of Vitamin World and Golfsmith International, currently on board of LKQ Corporation.
• ·Directors expected to stand for election at 2026 annual meeting of shareholders.

07-04-2026

Collegium Pharmaceutical, Inc. nominated Michael Donovan, a 60-year-old audit partner at Ernst & Young LLP with over 36 years of experience in life sciences audits, financings, and M&A, to stand for election at the 2026 Annual Meeting. Current director John Fallon, M.D., who has served since 2016, announced he will not stand for re-election and retire at the Annual Meeting as part of board refreshment and succession planning, with no disagreements with the Company.

• ·Michael Donovan served as Office Managing Partner of EY’s biotechnology office in Kendall Square from 2014 to 2024 and East Region Biotechnology Leader.
• ·Mr. Donovan holds a B.S. in Business Administration from Merrimack College and is a Certified Public Accountant (active).
• ·Events: Fallon announcement on April 2, 2026; Donovan nomination approved on April 6, 2026.

07-04-2026

ADTRAN Holdings, Inc. entered into a second amendment to CEO Thomas R. Stanton's employment agreement on April 6, 2026, eliminating annual PSUs tied to relative total shareholder return (TSR), adjusting long-term financial plan PSUs to be based on Adjusted EBIT subject to TSR adjustment, and modifying anticipated RSU and PSU values. On April 1, 2026, the Compensation Committee approved target long-term PSU awards under the 2024 Employee Stock Incentive Plan for the 2026-2028 performance period to Stanton (170,723 shares), Chief Revenue Officer James D. Wilson (24,908 shares), and CFO Timothy Santo (28,252 shares), with a similar award planned for CTO Christoph Glingener pending subsidiary approvals. The Company will not grant annual market-based PSUs to named executive officers going forward.

• ·Performance period for PSUs: January 1, 2026 through December 31, 2028
• ·Amendment approved by Board upon Compensation Committee recommendation
• ·Exhibits include Second Amendment to CEO Employment Agreement (10.1), Form of 2026 3-Year Performance Shares Agreement (10.2), and Form of 2026 CEO 3-Year Performance Shares Agreement (10.3)

07-04-2026

Kura Sushi USA reported fiscal Q2 2026 total sales of $80.0 million, up from $64.9 million YoY, driven by 8.6% comparable restaurant sales growth (4.3% traffic and 4.3% price/mix), with operating loss narrowing to $2.2 million from $4.6 million and Adjusted EBITDA rising to $5.5 million from $2.7 million. However, food and beverage costs increased to 30.4% of sales from 28.7% due to tariffs, other costs rose to 14.5% from 13.5%, and the company still posted a net loss of $1.7 million. Restaurant-level operating profit improved to $14.6 million or 18.2% of sales from $11.2 million or 17.3%.

• ·Company opened one new restaurant in Pflugerville, Texas during Q2 FY2026; subsequent openings: Orange, California; Goodyear, Arizona; Union City, California; Wellington, Florida.
• ·FY2026 guidance: Total sales $333-335 million; 16 new restaurants (unit growth >20%); average net capex ~$2.5 million per unit; G&A ~12.0% of sales excluding litigation; restaurant-level operating profit margins 18.0-18.5%.
• ·88 locations across 22 states and Washington DC as of filing.

07-04-2026

International Tower Hill Mines Ltd. (TSX: ITH, NYSE American: THM) announced the appointment of Mr. Andrew ('Andy') Cole to its Board of Directors effective April 1, 2026. Mr. Cole brings over 35 years of experience in metals and mining, including as General Manager of the Donlin Gold Project where he secured major permits, and roles at Barrick Gold's Goldstrike Mine and U.S. Operations. ITH Board Chair Marcelo Kim stated that Cole's expertise will be instrumental in advancing the Livengood Gold Project through feasibility, permitting, and early development.

• ·Mr. Cole holds a Bachelor of Science in Material Sciences and Engineering from University of Arizona and MBA from University of Nevada.
• ·Mr. Cole is a member of Society of Mining Engineers (SME) and was honored as SME's Miner of the Year in 2019.
• ·Mr. Cole has served on Perpetua Resources Board of Directors since 2024.

07-04-2026

Mark Thoenes, the Sole Disinterested Director of Kaival Brands Innovations Group, Inc., provided a fairness opinion pursuant to DGCL §144, concluding that the proposed employment arrangements and equity grants for CEO Eric Mosser and CFO Eric Morris, including an amendment to increase the reserve under the Amended and Restated 2020 Stock and Incentive Compensation Plan to 100,000,000 shares, are fair and reasonable to the Company and its stockholders from a financial point of view. The arrangements emphasize a heavily equity-oriented structure to align executive interests with long-term stockholder value, given the Company's cash-conservative position and post-Nasdaq delisting recovery strategy. No specific cash commitments were highlighted, focusing instead on retention incentives and minimal near-term financial impact.

• ·Opinion dated March 12, 2026
• ·Filing date: April 07, 2026
• ·Evaluation considers market comparisons with OTC/recovery-stage companies and tax/accounting implications

07-04-2026

Green Dot Corporation's Compensation Committee approved a one-time discretionary bonus opportunity for CEO William I. Jacobs of up to $1,250,000 for his service from January 8, 2026, through the closing of the proposed merger under the Agreement and Plan of Merger dated November 23, 2025. The bonus amount, if any, will be determined based on Jacobs' and the Company's performance and paid upon his cessation as CEO at closing. No other financial metrics or performance data are disclosed.

• ·Bonus eligibility requires continued service as CEO through merger closing
• ·Bonus determination by Compensation Committee in its sole discretion immediately prior to closing

07-04-2026

On April 1, 2026, the Compensation Committee of Unusual Machines, Inc. approved immediate salary increases for senior management, setting annual base salaries at $350,000 for CEO Dr. Allan Evans and $300,000 each for CFO Brian Hoff, President Andrew Camden, and Chief Revenue Officer Stacy Wright. No other changes to officer roles or departures were reported. This adjustment represents increased compensation costs for the executive team.

07-04-2026

Levi Strauss & Co. announced that Executive Vice President and Chief Financial & Growth Officer Harmit Singh will retire after a planned transition, during which he will serve as Special Advisor following the appointment of a successor. The company has commenced a comprehensive search for a new CFGO with assistance from a leading executive search firm to ensure continuity. CEO Michelle Gass highlighted Singh's 13-year contributions, including taking the company public, DTC transformation, and building a high-caliber finance team.

• ·Singh joined LS&Co. in 2013 as CFO.
• ·Singh's role expanded in 2023 to Chief Growth Officer.
• ·Prior roles: CFO at Hyatt Hotels Corporation; Division CFO at Yum! Restaurants International and Pizza Hut.

07-04-2026

PSQ Holdings, Inc. announced that James Rinn will step down as CFO effective April 30, 2026, to pursue another opportunity but will remain a Class III Director on the Board. Effective May 1, 2026, Michael Pena, current SVP of Finance, is appointed CFO and Treasurer, while Krista Wenzel, current SVP of Finance and Accounting, is named Chief Accounting Officer. CEO Dusty Wunderlich praised Rinn's contributions to the fintech transition and expressed confidence in Pena and Wenzel's alignment with the company's focus on disciplined capital allocation and financial controls.

• ·Michael Pena previously served as CFO of Credova from August 2021 to March 2024 and played a key role in its acquisition by PSQ Holdings.
• ·Krista Wenzel joined PSQ Holdings as VP of Accounting in September 2024 and became SVP of Finance & Accounting in November 2025.
• ·New structure: Pena focuses on financial planning, capital allocation, operational finance; Wenzel leads accounting, reporting, auditing.

07-04-2026

AppLovin Corporation announced executive succession plans: Basil Shikin will transition from Chief Technology Officer to Distinguished Engineer effective July 1, 2026, succeeded by Giovanni Ge as CTO; Victoria Valenzuela will retire as Chief Administrative & Legal Officer effective August 1, 2026, succeeded by Corina Cacovean as Chief Legal Officer. Craig Billings was appointed as independent Chairperson of the Board, succeeding his role as Lead Independent Director, while Alyssa Harvey Dawson will not stand for re-election at the 2026 Annual Meeting.

• ·Giovanni Ge joined AppLovin in November 2022 and led development of Axon 2.0.
• ·Corina Cacovean joined via acquisition of Machine Zone in 2020 and has served as Deputy General Counsel since September 2023.
• ·Craig Billings has been on the Board since the IPO and first engaged with AppLovin as a customer in 2013.
• ·Filing date: April 7, 2026; 2026 Annual Meeting of Stockholders referenced.

07-04-2026

Duos Technologies Group, Inc. appointed Douglas Recker as Chief Executive Officer and President effective April 1, 2026, following Charles Ferry's resignation from the CEO role; Ferry remains a Director and continues as CEO of New APR Energy, LLC, in which the Company holds a 5% equity interest. Ferry's equity award agreement, originally granting 552,889 shares vesting on December 31, 2027, was amended to 261,445 shares, now conditioned on his continued service as Director. The amendment is detailed in Exhibit 10.1.

• ·Original Equity Award Agreement effective January 1, 2025, with three-year cliff vesting on December 31, 2027.
• ·Common stock par value $0.001 per share, traded as DUOT on Nasdaq.
• ·Event reported April 1, 2026; filing dated April 7, 2026.

07-04-2026

BlackSky Technology Inc. announced the resignation of Tracy Ward as Senior Vice President, Controller, and Principal Accounting Officer, effective April 24, 2026, to pursue another opportunity, with no disputes or disagreements with the company. Henry Dubois, the current Chief Financial Officer and Principal Financial Officer, has been appointed as the new Principal Accounting Officer effective upon Ms. Ward's departure, with no new compensatory arrangements. Background on Mr. Dubois is available in the company's proxy statement filed on July 24, 2025.

• ·Resignation informed to company on April 2, 2026.
• ·Filing signed by Christiana Lin on April 7, 2026.

07-04-2026

Mattel, Inc. announced that Steve Totzke, President and Chief Commercial Officer, will step down effective May 1, 2026, and transition to Executive Advisor and President, Strategic Transition through December 31, 2026. Sanjay Luthra, Executive Vice President and Managing Director of EMEA and Global Direct-to-Consumer, has been promoted to succeed Totzke as Chief Commercial Officer, reporting to Chairman and CEO Ynon Kreiz. The announcement highlights Totzke's contributions to commercial growth and Luthra's successful leadership in EMEA, ensuring a smooth handover amid a positive outlook on Mattel's brand-centric strategy.

• ·Steve Totzke joined Mattel in 1996, appointed Chief Commercial Officer in 2018, and promoted to President in 2022; served on boards of Toy Association, Mattel Children’s Foundation, and Advisory Board for Women in Toys, Licensing, and Entertainment Association; inducted into Canadian Toy Association Hall of Fame in 2025.
• ·Sanjay Luthra joined Mattel India in 2003, held leadership roles in Eastern Europe and Canada; Chairman of Toy Industries of Europe for past seven years; will be based in El Segundo, California.

07-04-2026

On April 1, 2026, Stanley A. Moore resigned from the Board of Ares Industrial Real Estate Income Trust Inc., effective immediately, with no disagreements with management, operations, policies, or practices. The Board appointed Scott W. Lang as an independent director, effective the same date, and assigned him to the conflicts resolution committee and audit committee. The Company entered into a standard indemnification agreement with Mr. Lang.

• ·Mr. Lang's professional background: CFO of KickCharge Creative since April 2025; Operating Partner/Board Member at Shore Capital Partners since January 2023; COO/CFO of All Metals Industries/Gerber Metal Supply from February 2023 to April 2025; prior senior roles at FirstService Residential, Everest Group International, and investment banks.
• ·Mr. Lang holds an M.B.A. from Columbia University and B.S. in Accounting from SUNY Oswego; Certified Public Accountant in New York.
• ·No arrangements or understandings for Mr. Lang's selection as director.
• ·No transactions with Mr. Lang required to be reported under Item 404(a) of Regulation S-K.
• ·Indemnification agreement filed as Exhibit 10.6 to Post-Effective Amendment No. 1 to Form S-11 (Reg. No. 333-200594) on July 1, 2016.

07-04-2026

On April 1, 2026, Ares Real Estate Income Trust Inc. issued 1,020,998 Class S-PR shares for gross proceeds of $8,392,942 and 1,569,934 Class I-PR shares for $12,747,866 pursuant to Regulation D exemptions, including distribution reinvestment plan activity. On April 7, 2026, director Brian P. Mathis resigned from the Board with no disagreements, and Bryan B. Sanchez was appointed as an independent director, also joining the conflicts resolution and nominating and corporate governance committees. The company entered into a standard indemnification agreement with Mr. Sanchez.

• ·Mr. Mathis’s resignation was not the result of any disagreement with management, the Company or its operations, policies or practices.
• ·No arrangements or understandings between Mr. Sanchez and any other persons pursuant to which he was selected as a director.
• ·No transactions between the Company and Mr. Sanchez required to be reported under Item 404(a) of Regulation S-K.
• ·Mr. Sanchez's experience includes CEO of Lionstone Investments (2021-2023), Senior Advisor at Boston Consulting Group (since 2024), M.B.A. from Harvard Business School.

07-04-2026

ATN International, Inc. (Nasdaq: ATNI) announced the appointment of Naji Khoury as President and Chief Executive Officer, effective April 20, 2026, succeeding Brad Martin, who is stepping down from his CEO and Board roles but will serve in an advisory capacity through the end of May 2026. Khoury brings nearly 30 years of telecommunications experience, including 14 years at Liberty Communications Puerto Rico where he was CEO for the last six years, positioning the company for growth in its digital infrastructure and communications services. The Board praised Martin's contributions to operational improvements and network investments, ensuring a smooth transition.

• ·Brad Martin to remain in advisory capacity through end of May 2026
• ·Company operates in US, Caribbean, focusing on rural/remote markets with wireless, wireline, fiber optic, and tower services
• ·Investor contacts: IR@atni.com and kbuchhorn@threepa.com

07-04-2026

Capital One Financial Corporation completed its acquisition of Brex Inc. on April 7, 2026, for approximately $2.56 billion in cash and 10,646,306 shares of common stock, pursuant to a Merger Agreement dated January 22, 2026. The cash payment is subject to customary post-closing adjustments, and the stock issuance was exempt from registration under Section 4(a)(2) of the Securities Act. The Board also approved a special award of 11,041 restricted stock units valued at approximately $2.0 million to Frank LaPrade, Chief Enterprise Services Officer and Chief of Staff to the CEO, for his contributions to the transaction and anticipated integration work.

• ·Merger Agreement dated January 22, 2026.
• ·RSUs vest in three equal annual installments on the first, second, and third anniversaries of the grant date, settling 100% in Company Common Stock.
• ·Cash payment subject to customary post-closing adjustment.

07-04-2026

Atlas Lithium Corporation announced the immediate resignation of Director Rodrigo Menck on April 1, 2026, for personal reasons with no disagreements on company operations, policies, or practices. The Board appointed Admiral (Ret.) Flávio Augusto Viana Rocha, a former Four-Star Brazilian Navy Admiral with extensive government, military, and board experience, as an independent director effective April 6, 2026, and assigned him to the Audit Committee. Admiral Rocha will receive a monthly cash board service fee of approximately US$9,700, with no equity awards or related party transactions.

• ·Admiral Rocha is independent under Nasdaq rules and has no family relationships with any director or officer.
• ·Admiral Rocha served 43 years in Brazilian Navy, held Minister-level government roles, and has board experience in energy and insurance sectors.
• ·No arrangements or understandings pursuant to which Admiral Rocha was selected as director.

07-04-2026

Corbus Pharmaceuticals announced broad FDA alignment on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, supporting potential accelerated approval on ORR and full approval on OS benefit, with study initiation planned for mid-2026 in HNSCC. Updated monotherapy data from Phase 1/2 will be presented at ASCO 2026, and first-line combo data with Keytruda expected in Q4 2026. However, Dr. Dominic Smethurst is stepping down as Chief Medical Officer effective June 30, 2026.

• ·FDA granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer.
• ·ASCO 2026 Annual Meeting: May 29 – June 2, Chicago; includes CRB-701 response durability and HNSCC subgroup analysis.
• ·Previous data presented at ESMO 2025.
• ·CRB-701 licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.

07-04-2026

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective April 1, 2026, with Mr. Goldan also serving as Chairman of the Audit Committee. Mr. Goldan brings over two decades of financial leadership experience, including current CFO role at Syndax Pharmaceuticals since 2022, prior CFO positions at Optinose, Fibrocell, NuPathe, PuriCore plc, and Biosyn, and roles at ViroPharma and KPMG. The appointment is intended to strengthen leadership for capital markets, corporate development, operational scaling, and advancing commercial-stage growth, particularly for ZEVASKYN.

• ·Filing date: April 07, 2026
• ·Appointment effective date: April 1, 2026
• ·Abeona's manufacturing facility located in Cleveland, Ohio for ZEVASKYN commercial production

07-04-2026

Azenta, Inc. (Nasdaq: AZTA) appointed Trey Martin as President of its Multiomics business effective April 6, 2026, to accelerate execution of its long-range Multiomics plan outlined at the December 2025 Investor Day, focusing on scaling synthesis capabilities and profitable growth. Ginger Zhou stepped down from the role but will provide advisory support through November 2026 for a smooth transition. The announcement highlights Martin's 30+ years of experience from Maravai Life Sciences, Danaher, and IDT.

• ·Trey Martin previously served as CEO of Maravai Life Sciences and in senior roles at Danaher, including President of IDT.
• ·Azenta headquartered in Burlington, MA, with operations in North America, Europe, and Asia.
• ·Forward-looking statements subject to risks detailed in SEC filings.

07-04-2026

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) announced the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026, transitioning from his current role as Medical Director since January 2025. Dr. Marshall, an experienced interventional radiologist, will lead medical strategy, clinical development, and strategic initiatives for the company's PEDD platform and oncology products. The move is positioned to accelerate clinical and economic data advancement amid strong physician engagement, with no reported setbacks in leadership transition.

• ·Dr. Marshall's background includes interventional radiology fellowship at Weill Cornell and Memorial Sloan Kettering, faculty roles at LSU Health Sciences Center and Tulane University.
• ·Company's FDA-cleared devices utilize PEDD for hepatic arterial infusion (liver tumors) and pancreatic retrograde venous infusion (pancreatic tumors).
• ·TriSalus is in final stages of data completion for phase 1 clinical trials of nelitolimod and plans to explore partnerships.

07-04-2026

On April 1, 2026, Jesse Channon resigned as President of The Cannabist Company Holdings Inc. effective immediately, transitioning to a non-employee consultant role via a Consulting Engagement Agreement. Under the agreement, he will receive $10,000 per month for corporate services, with an initial term from April 2, 2026, to July 3, 2026, including customary confidentiality provisions. The filing was made on April 7, 2026, with the full agreement attached as Exhibit 10.1.

• ·Mr. Channon joined the Company in 2019 as Chief Growth Officer, later becoming Chief Commercial Officer before President.
• ·Consulting Agreement contains customary confidentiality provisions.

07-04-2026

Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) announced the appointment of Nancy Zakhour as an independent director, serving on the Audit, Compensation, and Nominating and Corporate Governance Committees, and Saleh Sagr, the President and CEO, as a director, both effective April 8, 2026. Ms. Zakhour brings extensive experience in renewable energy, oil & gas, investment banking, and carbon capture projects from roles at Clean Energy Services, Piper Sandler, Occidental Petroleum, and others. The board and leadership highlighted these additions as strengthening strategic oversight and supporting long-term growth amid the energy transition.

• ·Nancy Zakhour holds a Bachelor of Engineering in Electrical and Computer Engineering from the American University of Beirut and an MBA from Rice University; recipient of SPE Regional Completions Optimization and Technology Award and Hart Energy’s 40 Under Forty Award.
• ·Saleh Sagr, age 56, has served as President and CEO since June 7, 2025, with over 30 years in pipeline coating, industrial manufacturing, and international operations.
• ·Company contact: Perma-Pipe Investor Relations (847) 929-1200, investor@permapipe.com.

07-04-2026

On April 7, 2026, Braze, Inc. announced that Susan Wiseman intends to retire as the company's General Counsel and Secretary on or before June 30, 2026. The 8-K filing was signed by Isabelle Winkles, Chief Financial Officer. No successor or additional details on transition were provided.

07-04-2026

On April 7, 2026, AI Era Corp. accepted the resignation of Chiyuan Deng as Chief Financial Officer, effective immediately, though he will continue serving as President and director with no disagreements on company matters. The Board appointed Dzmitry Kastahorau, age 35 with over 10 years of international finance experience, as the new CFO and Principal Accounting Officer. His employment agreement includes a $300,000 sign-on bonus in restricted stock, $60,000 annual base salary, 1,500,000 stock options vesting over three years, and up to 1,000,000 performance shares.

• ·Employment Agreement dated April 6, 2026, with 3-year initial term and automatic renewals.
• ·Stock options include full acceleration upon Change of Control or termination without Cause.
• ·No family relationships between Mr. Kastahorau and any director/executive officer; no disclosable transactions under Item 404(a).
• ·Mr. Kastahorau's education: Master of International Finance from EADA Business School; Bachelor of Business Administration from La Salle and International University of Monaco.

07-04-2026

Stoke Therapeutics, Inc. (Nasdaq: STOK) announced the appointment of Clare Kahn, Ph.D., an experienced leader in regulatory strategy and drug development from roles at X-VAX Technology, Pfizer, and GlaxoSmithKline, to its Board of Directors. The appointment occurs as the company advances its Phase 3 study of zorevunersen, an investigational antisense oligonucleotide for Dravet syndrome, under a collaboration with Biogen. Dr. Kahn's expertise in rare genetic diseases is expected to support efforts to deliver a potential first-in-class disease-modifying treatment.

• ·Zorevunersen has received orphan drug designation from FDA and EMA, rare pediatric disease designation, and Breakthrough Therapy Designation from FDA for Dravet syndrome with confirmed SCN1A mutation not associated with gain-of-function.
• ·Stoke retains exclusive rights for zorevunersen commercialization in U.S., Canada, and Mexico; Biogen has exclusive rest of world rights.
• ·Dravet syndrome caused by mutations in SCN1A gene leading to insufficient NaV1.1 protein.

07-04-2026

E. Spencer Abraham informed the NRG Energy, Inc. Board of his resignation effective April 3, 2026, for personal reasons, with no disagreement on operations, policies, or practices. This decision aligns with the Board's succession planning, as disclosed in the proxy statement filed March 18, 2026, and he is not standing for re-election at the annual stockholder meeting on April 30, 2026.

• ·Resignation notice provided to Board on April 2, 2026.
• ·8-K filed on April 7, 2026.
• ·Company headquartered at 1301 McKinney Street, Houston, Texas 77002.